Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Amer Sports Inc (AS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Amer Sports Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while Amer Sports Inc trades at $34.2 (market cap $20.25B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Amer Sports Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AS | |
|---|---|---|
Market Cap | $39.89B | $20.25B |
Sector | Health | Technology |
52-Week High | $491.22 | $41.96 |
52-Week Low | $278.09 | $29.54 |
Enterprise Value | $38.15B | $20.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Amer Sports (AS) trades at $34.80, up 2.75% today, with strong Q1 2026 earnings beating estimates and raised full-year guidance. Technicals show a bearish trend near key support at $33, while fundamentals reflect robust revenue growth of 32% year-over-year and a 58.23% gross margin. Analyst sentiment is overwhelmingly positive with 12 buy ratings and a $56 consensus target, indicating 61% upside potential from current levels.
The outlook remains favorable given earnings momentum and raised guidance, but risks include reliance on Arc'teryx brand sustainability and competitive pressures. Valuation metrics like a P/E of 43.49 suggest premium pricing, requiring continued execution to justify upside. Net positive cash flow and institutional support provide stability amid technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Amer Sports Inc
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →
